Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2006-10-27
2010-11-16
Blanchard, David J. (Department: 1643)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S133100, C424S155100, C424S156100, C435S069600, C530S387300, C530S388800, C530S388850
Reexamination Certificate
active
07833528
ABSTRACT:
Embodiments of the invention relate to a method for treating target cells, tissues or pathogens in a subject, comprising administering a non-covalently bound complex which comprises a multispecific targeting protein and a hapten-enzyme covalent conjugate, followed by administration of a prodrug that is converted to an active drug by the enzyme. Other embodiments of the invention further relate to kits comprising the non-covalently bound complex or the components to prepare the complex.
REFERENCES:
patent: 4468457 (1984-08-01), Goldenberg et al.
patent: 4735210 (1988-04-01), Goldenberg
patent: 4737453 (1988-04-01), Primus
patent: 4792521 (1988-12-01), Shochat
patent: 4818709 (1989-04-01), Primus et al.
patent: 4863713 (1989-09-01), Goodwin et al.
patent: 4971792 (1990-11-01), Steplewski et al.
patent: 5078998 (1992-01-01), Bevan et al.
patent: 5101827 (1992-04-01), Goldenberg
patent: 5128119 (1992-07-01), Griffiths
patent: 5183756 (1993-02-01), Schlom
patent: 5225541 (1993-07-01), Hackett et al.
patent: 5256395 (1993-10-01), Barbet et al.
patent: 5274076 (1993-12-01), Barbet et al.
patent: 5328679 (1994-07-01), Hansen et al.
patent: 5469854 (1995-11-01), Unger et al.
patent: 5502037 (1996-03-01), Kondratyev
patent: 5503987 (1996-04-01), Wagner et al.
patent: 5534254 (1996-07-01), Huston
patent: 5534326 (1996-07-01), Trokhan et al.
patent: 5591828 (1997-01-01), Bosslet et al.
patent: 5683694 (1997-11-01), Bagshawe et al.
patent: 5693762 (1997-12-01), Queen et al.
patent: 5697902 (1997-12-01), Goldenberg
patent: 5716595 (1998-02-01), Goldenberg
patent: 5746996 (1998-05-01), Govindan et al.
patent: 5753206 (1998-05-01), McBride et al.
patent: 5772981 (1998-06-01), Govindan et al.
patent: 5776093 (1998-07-01), Goldenberg
patent: 5776094 (1998-07-01), Goldenberg
patent: 5776095 (1998-07-01), Goldenberg
patent: 5837242 (1998-11-01), Holliger et al.
patent: 5837243 (1998-11-01), Deo et al.
patent: 5846741 (1998-12-01), Griffiths et al.
patent: 5851527 (1998-12-01), Hansen
patent: 5959083 (1999-09-01), Bosslet et al.
patent: 6010680 (2000-01-01), Govindan et al.
patent: 6077499 (2000-06-01), Griffiths et al.
patent: 6096289 (2000-08-01), Goldenberg
patent: 6121424 (2000-09-01), Whitlow et al.
patent: 6126916 (2000-10-01), McBride et al.
patent: 6187284 (2001-02-01), Griffiths
patent: 6217869 (2001-04-01), Meyer et al.
patent: 6540980 (2003-04-01), Blumenthal et al.
patent: 6962702 (2005-11-01), Hansen et al.
patent: 7074405 (2006-07-01), Hansen et al.
patent: 7138103 (2006-11-01), Goldenberg et al.
patent: 2003/0068322 (2003-04-01), Hansen
patent: 0263046 (1988-04-01), None
patent: 0419387 (1991-03-01), None
patent: 0511011 (1992-10-01), None
patent: 0517024 (1992-12-01), None
patent: 0623675 (1994-11-01), None
patent: 921782 (1992-12-01), None
patent: 9604313 (1996-02-01), None
patent: 9741898 (1997-11-01), None
patent: 9808875 (1998-03-01), None
patent: 9966951 (1999-12-01), None
patent: 0016808 (2000-03-01), None
patent: 0034317 (2000-06-01), None
patent: 0043541 (2000-07-01), None
Bardies et al. The Journal of Nuclear Medicine 37(11):1853-1859, 1996.
Danks et al. Clinical Cancer Research 5:917-924, Apr. 1999.
Haisma et al. Blood, 92(1):184-190, Jul. 1, 1998.
Alt et al., “Novel tetravalent and bispecific IgG-like antibody molecules combining single-chain diabodies with the immunoglobulin gamma1 Fc or CH3 region”, FEBS Lett. Jul. 2, 1999; 454(1-2):90-4.
Arano et al., “Reassessment of Diethylenetriaminepentaacetic Acid (DTPA) as a Chelating Agent for Indium-111 Labeling of Polypeptides Using a Newly Synthesized Monoreactive DTPA Derivative”, J. Med. Chem. 1996, 39, 3451-3460.
Bamias and Epenetos, “Two-Step Strategies for the Diagnosis and Treatment of Cancer with Bioconjugates”, Antibody, Immunoconj. Radiopharm., 5(4):385-395, 1992.
Barbet et al., “Radioimmunotherapy of LS174T Colon Carcinoma in Nude Mice Using an Iodine-131-Labeled Bivalent Hapten Combined with an Anti-CEA x Anti-Indium-DTPA Bispecific Antibody”, Tumor Biology, 18 (Suppl. 2), p. 31 (1997).
Barbet et al., “Radioimmundetection of medullary thyroid carcinoma using Indium-111 bivalent hapten and Anti-CEA x Anti-DTPA-Indium bispecific antibody”, J. Nucl. Med. Jul. 1998; 39(7):1172-8.
Boden et al., “Preliminary Study of the Metal Binding Site of an Anti-DTPA-Indium Antibody by Equilibrium Binding Immunoassays and Immobilized Metal Ion Affinity Chromatography”, Bioconjugate Chem. 1995, 6, 373-379.
Bos et al., “In Vitro Evaluation of DNA-DNA Hybridization as a Two-Step Approach in Radioimmunotherapy of Cancer”, Cancer Res. 54, 3479-3486, Jul. 1, 1994.
Bosslet et al., “Generation of Bispecific Monoclonal Antibodies for Two Phase Radioimmunotherapy”, Br. J. Cancer May 1991; 63(5):681-6.
Chatziioannou et al., “Micropet I: Performance Evaluation of a Very High Resolution PET Scanner for Imaging Small Animals”, J. Nucl. Med. 38(5), May 1997 Suppl., No. 19, p. 7P-8P.
Cruse and Lewis, Illustrated Dictionary of Immunology, CRC Press, 1995, p. 117.
De Boisferon et al., “Enhanced Targeting Specificity to Tumor Cells by Simultaneous Recognition of Two Antigens”, Bioconj. Chem. 2000, 11, 452-460.
De Jonge et al., Production and Characterization of Bispecific Single-Chain Antibody Fragments, Mol. Immunol. 32 (17/18):1405-1412 (1995).
Dubel et al., “Reconstitution of human pancreatic RNase from two separate fragments fused to different single chain antibody fragments: on the way to binary immunotoxins”, Tumor Targeting (1999) 4, 37-46.
Gautherot et al., “Radioimmunotherapy of LS174T Colon Carcinoma in Nude Mice Using an Iodine-131-Labeled Bivalent Hapten Combined with an Anti-CEA x Anti-Indium-DTPA Bispecific Antibody”, J. Nucl. Med. 38(5), May 1997 Suppl., No. 18, p. 7P.
Gautherot et al., “Delivery of therapeutic doses of radioiodine using bispecific antibody-targeted bivalent haptens”, J. Nucl. Med. Nov. 1998; 39(11):1937-43.
Gautherot et al., “Therapy for colon carcinoma xenografts with bispecific antibody-targeted, iodine-131-labeled bivalent hapten”, Cancer Dec. 15, 1997; 80(12 Suppl.):2618-23.
Gold et al., “Murine Monoclonal Antibodies to Colon-specific Antigen p1”, Cancer Res. 50, 6405-6409, Oct. 1, 1990.
Goodwin et al., “Pre-targeted immunoscintigraphy of murine tumors with Indium-111-labeled bifunctional haptens”, J. Nucl. Med. Feb. 1988; 29(2):226-34.
Greenwood et al., “The Preparation of 131I-Labelled Human Growth Hormone of High Specific Radioactivity”, Biochem. J. (1963) 89, 114-123.
Hayden et al., “Single-chain mono- and bispecific antibody derivatives with novel biological properties and antitumour activity from a COS cell transient expression system”, Therapeutic Immunology 1994, 1, 3-15.
Hawkins et al., “Delivery of radionuclides to pretargeted monoclonal antibodies using dihydrofolate reductase and methotrexate in an affinity system”, Cancer Res. May 15, 1993; 53(10 Suppl.):2368-73.
Hosono et al., “Biodistribution and dosimetric study in medullary thyroid cancer xenograft using bispecific antibody and Iodine-125-labeled bivalent hapten”, J. Nucl. Med. Sep. 1998; 39(9):1608-13.
Kaneko et al., “New Hydrazone Derivatives of Adriamycin and Their Immunoconjugates-a Correlation between Acid Stability and Cytotoxicity”, Bioconj. Chem. 2(3):133-141 (1991).
Karacay et al., “Studies on a humanized anti-CEA x murine anti-(In-DTPA) bispecific antibody construct for radioimmunotherapy of CEA-positive tumors”, Proc. Natl. Acad. Sci. USA, vol. 40, p. 644, Mar. 1999.
Karacay et al., “Pretargeting studies with a humanized anti-CEA x Murine anti(In-DTPA) bispecific antibody construct and Tc-99m/Re-188 labeled peptide”, J. Nucl. Med. vol. 40, No. 5 Suppl., p. 225, May 1999.
Karacay et al., “Pretargeting Studies with a Murine Anti-Colon-Specific Antigen-P (CSAp) x Chimeric Anti-[Indium-DTPA] Bispecific Antibody and T
Govindan Serengulam V.
Griffiths Gary L.
Hansen Hans J.
Blanchard David J.
Immunomedics Inc.
Nakashima Richard A.
LandOfFree
Use of multispecific, non-covalent complexes for targeted... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of multispecific, non-covalent complexes for targeted..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of multispecific, non-covalent complexes for targeted... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4239362